{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:44:01Z","timestamp":1780065841938,"version":"3.54.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Daily oral HIV preexposure prophylaxis (PrEP) delivery requires quarterly clinic visits for HIV testing and drug refilling that are costly to health systems and clients.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate whether 6-month PrEP dispensing supported with interim HIV self-testing (HIVST) results in noninferior PrEP continuation outcomes at 12 months compared with standard quarterly clinic visits.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This randomized noninferiority trial was conducted from May 2018 to May 2021 with 12 months of follow-up among PrEP clients aged 18 years or older who were returning for their first refill at a research clinic in Kiambu County, Kenya.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Participants were randomized 2:1 to (1) 6-month PrEP dispensing with semiannual clinic visits and interim HIVST at 3 months or (2) standard-of-care (SOC) PrEP delivery with 3-month dispensing, quarterly clinic visits, and clinic-based HIV testing.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Prespecified 12-month outcomes included recent HIV testing (any in past 6 months), PrEP refilling, and PrEP adherence (detectable tenofovir-diphosphate concentrations in dried blood spots). Binomial regression models were used to estimate risk differences (RDs), and a 1-sided 95% CI lower bound (LB) of \u221210% or greater was interpreted as noninferior.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 495 participants were enrolled, with 329 enrolled in the intervention group and 166 enrolled in the SOC group; 330 (66.7%) were women, 295 (59.6%) were in serodifferent relationships, and the median (IQR) age was 33 (27-40) years. At 12 months, 241 individuals in the intervention group (73.3%) and 120 in the SOC group (72.3%) returned to clinic. In the intervention group, recent HIV testing was noninferior (230 individuals [69.9%]) compared with the SOC group (116 [69.9%]; RD, \u22120.33%, 95% CI LB, \u22127.44%). PrEP refilling in the intervention group (196 [59.6%]) was inconclusive compared with the SOC group (104 [62.7%]; RD, \u22123.25%; 95% CI LB, \u221210.84%), and PrEP adherence was noninferior in the intervention group (151 [45.9%]) compared with the SOC group (70 [42.2%]; RD, 4.96%; 95% CI LB, \u22122.46%). No HIV seroconversions were observed over the follow-up period.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this analysis of secondary trial end points at 1 year, semiannual PrEP dispensing with interim HIVST resulted in noninferior recent HIV testing and PrEP adherence compared with SOC quarterly PrEP dispensing. This novel model has the potential to optimize PrEP delivery.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03593629<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.18590","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T15:01:03Z","timestamp":1686841263000},"page":"e2318590","source":"Crossref","is-referenced-by-count":10,"title":["Effect of 6-Month HIV Preexposure Prophylaxis Dispensing With Interim Self-testing on Preexposure Prophylaxis Continuation at 12 Months"],"prefix":"10.1001","volume":"6","author":[{"given":"Katrina F.","family":"Ortblad","sequence":"first","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley R.","family":"Bardon","sequence":"additional","affiliation":[{"name":"Department of Global Health, University of Washington, Seattle"},{"name":"Department of Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mogere","sequence":"additional","affiliation":[{"name":"Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kiptinness","sequence":"additional","affiliation":[{"name":"Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gakuo","sequence":"additional","affiliation":[{"name":"Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mbaire","sequence":"additional","affiliation":[{"name":"Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Global Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly R.","family":"Mugo","sequence":"additional","affiliation":[{"name":"Department of Global Health, University of Washington, Seattle"},{"name":"Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[{"name":"Department of Global Health, University of Washington, Seattle"},{"name":"Department of Epidemiology, University of Washington, Seattle"},{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"now with Gilead Sciences, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[{"name":"Department of Global Health, University of Washington, Seattle"},{"name":"School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"5","key":"zoi230565r3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41591-020-0872-x","article-title":"PrEP rollout in Africa: status and opportunity.","volume":"26","author":"Irungu","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"zoi230565r4","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/QAI.0000000000002625","article-title":"\u201cI just decided to stop:\u201d understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya.","volume":"87","author":"Ongolly","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"zoi230565r6","doi-asserted-by":"publisher","first-page":"e967","DOI":"10.1016\/j.ijid.2010.05.016","article-title":"Health-seeking patterns among participants of population-based morbidity surveillance in rural western Kenya: implications for calculating disease rates.","volume":"14","author":"Bigogo","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"1","key":"zoi230565r7","doi-asserted-by":"publisher","first-page":"21134","DOI":"10.7448\/IAS.19.1.21134","article-title":"\u201cSince both of us are using antiretrovirals, we have been supportive to each other\u201d: facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.","volume":"19","author":"Patel","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"zoi230565r8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/1472-6963-14-231","article-title":"Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.","volume":"14","author":"Mack","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"zoi230565r9","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S2214-109X(19)30534-0","article-title":"Effect of facility-based HIV self-testing on uptake of testing among outpatients in Malawi: a cluster-randomised trial.","volume":"8","author":"Dovel","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"8","key":"zoi230565r10","doi-asserted-by":"publisher","first-page":"e25561","DOI":"10.1002\/jia2.v23.8","article-title":"Uptake and impact of facility-based HIV self-testing on PrEP delivery: a pilot study among young women in Kisumu, Kenya.","volume":"23","author":"Wanga","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"zoi230565r11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13063-019-3521-2","article-title":"HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya.","volume":"20","author":"Ortblad","year":"2019","journal-title":"Trials"},{"issue":"7","key":"zoi230565r12","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2352-3018(22)00126-6","article-title":"Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial.","volume":"9","author":"Ngure","year":"2022","journal-title":"Lancet HIV"},{"issue":"1","key":"zoi230565r15","first-page":"e01710","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy.","volume":"62","author":"Anderson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"zoi230565r16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-inferiority.","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials"},{"issue":"7","key":"zoi230565r17","doi-asserted-by":"publisher","first-page":"e1893","DOI":"10.1093\/cid\/ciaa1872","article-title":"Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa.","volume":"73","author":"Stranix-Chibanda","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi230565r19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.9745\/GHSP-D-19-00286","article-title":"A qualitative assessment of provider and client experiences with 3- and 6-month dispensing intervals of antiretroviral therapy in Malawi.","volume":"8","author":"Hubbard","year":"2020","journal-title":"Glob Health Sci Pract"},{"issue":"1","key":"zoi230565r20","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/QAI.0000000000002109","article-title":"A field evaluation of point-of-care creatinine testing within a large PrEP implementation program in Western Kenya.","volume":"82","author":"Abuna","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"zoi230565r21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/QAI.0000000000001575","article-title":"Brief report: frequency of monitoring kidney function in HIV-uninfected persons using daily oral tenofovir disoproxil fumarate pre-exposure prophylaxis.","volume":"77","author":"Mugwanya","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"zoi230565r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170868","article-title":"Uptake and acceptability of oral HIV self-testing among community pharmacy clients in Kenya: a feasibility study.","volume":"12","author":"Mugo","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"zoi230565r23","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.v25.10","article-title":"The effectiveness, feasibility and acceptability of HIV service delivery at private pharmacies in sub-Saharan Africa: a scoping review.","volume":"25","author":"Kuo","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"zoi230565r24","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2021.683415","article-title":"Integrating pre-exposure prophylaxis delivery in public health family planning clinics: lessons learned from a programmatic implementation project in Kenya.","volume":"3","author":"Mugwanya","year":"2021","journal-title":"Front Reprod Health"},{"issue":"9","key":"zoi230565r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002885","article-title":"Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya.","volume":"16","author":"Mugwanya","year":"2019","journal-title":"PLoS Med"},{"issue":"1","key":"zoi230565r26","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3018(19)30335-2","article-title":"Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme.","volume":"7","author":"Kinuthia","year":"2020","journal-title":"Lancet HIV"},{"issue":"Suppl 1","key":"zoi230565r27","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/QAI.0000000000001210","article-title":"Counseling framework for HIV-serodiscordant couples on the integrated use of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention.","volume":"74","author":"Morton","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"zoi230565r28","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/QAI.0000000000002793","article-title":"Pills, injections, rings, or implants? PrEP formulation preferences of PrEP-experienced African women for HIV prevention.","volume":"88","author":"Ngure","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"zoi230565r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101507","article-title":"Preferences for pre-exposure prophylaxis for HIV: a systematic review of discrete choice experiments.","volume":"51","author":"Wulandari","year":"2022","journal-title":"EClinicalMedicine"},{"key":"zoi230565r18","author":"Mangale","year":"2022"},{"key":"zoi230565r1","unstructured":"World Health Organization. Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance. Accessed December 2, 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240053694"},{"key":"zoi230565r2","unstructured":"World Health Organization. WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). Accessed December 1, 2022. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/197906\/WHO_HIV_2015.48_eng.pdf"},{"key":"zoi230565r5","unstructured":"Ministry of Health. Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya. Accessed December 1, 2022. http:\/\/cquin.icap.columbia.edu\/wp-content\/uploads\/2017\/04\/ICAP_CQUIN_Kenya-ARV-Guidelines-2018-Final_20thAug2018.pdf"},{"key":"zoi230565r13","unstructured":"Ministry of Health. Kenya HIV estimates 2018. Accessed December 2, 2022. https:\/\/nsdcc.go.ke\/wp-content\/uploads\/2018\/11\/HIV-estimates-report-Kenya-20182.pdf"},{"key":"zoi230565r14","unstructured":"Equator Network. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Accessed April 14, 2023. https:\/\/www.equator-network.org\/reporting-guidelines\/consort\/"},{"key":"zoi230565r30","unstructured":"Joint United Nations Programme on HIV\/AIDS. In danger: UNAIDS global AIDS Update 2022. Accessed December 1, 2022. https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/in-danger-global-aids-update"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2806098\/ortblad_2023_oi_230565_1686167867.05851.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T15:01:07Z","timestamp":1686841267000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2806098"}},"subtitle":["A Randomized Noninferiority Trial"],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.18590","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}